Please assess the completion status of the following clinical trial:

Trial Title: Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male of female aged 3 months to \< 18 years with a body weight of at least 5 kg~* Diagnosis of either hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalization and administration of IV antibiotic therapy~* New or progressive imaging findings consistent with bacterial pneumonia~* Requirement for IV antibacterial treatment for pneumonia~* Other inclusion criteria may apply~Exclusion Criteria:~* Known resistance of the causative pathogen to ceftobiprole or IV standard-of-care cephalosporin treatment (± vancomycin)~* On mechanical ventilation~* Chest trauma with severe lung contusion or flail chest~* Acute respiratory distress syndrome~* Empyema or lung abscess~* Anatomical bronchial obstruction~* Active or currently treated pulmonary tuberculosis~* Atypical bacterial pneumonia, or viral pneumonia without bacterial superinfection, or need for antibiotic coverage with a macrolide~* Pertussis, chemical pneumonitis, or cystic fibrosis~* Severe immunodeficiency~* Significant laboratory abnormalities including: Hematocrit \<20%; absolute neutrophil count \<0.5x10⁹/L; platelet count \<50x10⁹/L; alanine aminotransferase, aspartate aminotransferase, or bilirubin \>5 times the age-specific upper limit of normal;~* Creatinine clearance \<50 mL/min/1.73 m²~* Use of systemic antimicrobial therapy for more than 24 hours in the 48 hours before randomization~* History of a previous clinically-relevant hypersensitivity or serious adverse reaction to beta lactam antibiotics or to vancomycin~* Poorly controlled seizure disorder~* Other exclusion criteria may apply

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ceftobiprole medocaril (Type: EXPERIMENTAL): Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
- IV standard-of-care cephalosporin (Type: ACTIVE_COMPARATOR): Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed.

Based on this trial design, predict the completion outcome and termination type (if applicable).